Summary
GlobalData, the industry analysis specialist's new report, "Parkinson's Disease-Pipeline Assessment and Market Forecasts to 2016" is an essential source of information and analysis on the global Parkinson's disease market. The report identifies the key trends shaping and driving the global Parkinson's disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Parkinson's disease sector. GlobalData estimated the global Parkinson's disease market to be valued at $3,178m in 2009. It is forecast to grow at 0.9% annually for the next seven years to reach $3,384m by 2016. This low growth is ascribed to patent expirations, subsequent entry of generics, weak developmental pipeline and the unknown cause of the disease continues to pose significant challenges for prospective market entrants, is expected to keep the market static. Ageing population would be a key driver of this market. The global Parkinson's disease market is not well served with current product options and boundless scope is available to new entrants that would capture value from underserved segments. Designing disease-modifying drugs rather than drugs for providing symptomatic relief is one of the key challenges of this market and could provide significant market for any company. GlobalData finds that the global Parkinson's disease market is increasingly hampered by lack of innovation. On the whole, the late stage pipeline consists of drugs that are aimed at the symptomatic treatment of the disease. There are 181 products in different developmental stages in 2010. Majorly, pipeline presents drugs that are aimed at symptomatic treatment of the disease. Balancing the pipeline with the huge burden of the disease and high expectations of patients, the pipeline is considered to be weak. If a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects such as dyskinesis, psychiatric side effects and obsessive compulsive behaviors. Currently, these are the biggest challenges preventing most pipeline products from capturing these unmet needs.

Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Parkinson's Disease Market: Market Characterization 6
2.1 Overview 6
2.2 Parkinson's Disease Market Size 6
2.3 Parkinson's Disease Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Parkinson's Disease Market 8
2.4.1 Drivers for the Parkinson's Disease Market 8
2.4.2 Barriers for the Parkinson's Disease Market 8
2.5 Opportunity and Unmet Need 9
2.5.1 Key Takeaway 10
3 Parkinson's Disease Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the PD Market 12
3.3.1 Stalevo (levodopa, carbidopa, entacapone) 12
3.3.2 Requip XL (ropinirole XL) 13
3.3.3 Azilect (rasagiline mesylate) 14
3.3.4 Mirapex/Sifrol/Mirapexin (pramipexole dihydrochloride) 15
3.4 Other Marketed Products for the Parkinson's Disease Market 16
3.4.1 Comtan (entacapone) 16
3.4.2 Tasmar (tolcapone) 16
3.5 Key Takeaway 19
4 Parkinson's Disease Market: Pipeline Assessment 20
4.1 Overview 20
4.2 Strategic Pipeline Assessment 20
4.2.1 Technology Trends Analytic Framework 20
4.3 Parkinson's Disease Therapeutics-Promising Drugs under Clinical Development 22
4.4 Molecule Profile for Promising Drugs under Clinical Development 23
4.4.1 Safinamide 23
4.4.2 Pimavanserin (ACP-103) 24
4.4.3 PD-02 25
4.4.4 SLV 308 (pardoprunox) 25
4.4.5 Lisuride (patch and subcutaneous (sc) infusion) 26
4.4.6 IPX066 27
4.5 Parkinson's Disease Therapeutics Market-Clinical Pipeline by Mechanism of Action 28
4.6 Parkinson's Disease Pipeline-Pipeline by Clinical Phases of Development 28
4.6.1 Parkinson's Disease Therapeutics-Phase III Clinical Pipeline 29
4.6.2 Parkinson's disease Therapeutics-Phase II Clinical Pipeline 31
4.6.3 Parkinson's Disease Therapeutics-Phase I Clinical Pipeline 33
4.6.4 Parkinson's Disease Therapeutics-Preclinical Pipeline 34
4.6.5 Parkinson's Disease Therapeutics-Discovery Pipeline 35
4.7 Discontinued/Suspended Drugs for Parkinson's Disease 36
4.8 Key Takeaway 37
5 Parkinson's Disease Market: Implications for Future Market Competition 38
6 Parkinson's Disease Market: Future Players in the Parkinson's Disease Market 40
6.1 Introduction 40
6.2 Merck Serono 40
6.2.1 Overview 40
6.2.2 CNS Portfolio 40
6.2.3 Parkinson's Disease Product Portfolio 41
6.3 Acadia Pharmaceuticals 42
6.3.1 Overview 42
6.3.2 CNS Portfolio 42
6.3.3 Parkinson's Disease Product Portfolio 42
6.4 Axxonis Pharma AG 43
6.4.1 Overview 43
6.4.2 CNS Portfolio 43
6.4.3 Parkinson's Disease Product Portfolio 43
6.5 Avicena Group Inc. 44
6.5.1 Overview 44
6.5.2 CNS Portfolio 44
6.5.3 Parkinson's Disease Product Portfolio 45
6.6 Solvay Pharmaceuticals 45
6.6.1 Overview 45
6.6.2 CNS Portfolio 45
6.6.3 Parkinson's Disease Product Portfolio 46
6.7 Impax Laboratories 47
6.7.1 Overview 47
6.7.2 CNS Portfolio 47
6.7.3 Parkinson's Disease Product Portfolio 47
7 Parkinson's Disease Market: Appendix 49
7.1 Market Definitions 49
7.2 Abbreviations 49
7.3 Research Methodology 50
7.3.1 Coverage 51
7.3.2 Secondary Research 51
7.3.3 Forecasting 51
7.3.4 Primary Research 53
7.3.5 Expert Panel Validation 54
7.4 Contact Us 54
7.5 Disclaimer 54
7.6 Sources 54

List of Tables
1.1 List of Tables
Table 1: Global Parkinson's Disease Market Revenue($m) Forecast 2001-2009 7
Table 2: Global Parkinson's Disease Market Revenue($m) Forecast 2009-2016 8
Table 3: Major Marketed Products Comparison in the Parkinson's Disease Market, 2010 18
Table 4: Parkinson's Disease Therapeutics-Most Promising Drugs under Clinical Development, 2010 22
Table 5: Parkinson's Disease Therapeutics-Phase III Clinical Pipeline, 2010 29
Table 6: Parkinson's Disease Therapeutics-Phase II Clinical Pipeline, 2010 31
Table 7: Parkinson's Disease Therapeutics-Phase I Clinical Pipeline, 2010 33
Table 8: Parkinson's Disease Therapeutics-Preclinical Pipeline, 2010 34
Table 9: Parkinson's Disease Therapeutics-Discovery Pipeline, 2010 35
Table 10: List of Discontinued Drugs for Parkinson's Disease, 2010 36
Table 11: Merck Serono-CNS Marketed Products, 2010 40
Table 12: Merck Serono-CNS Pipeline Products, 2010 41
Table 13: Acadia Pharmaceuticals-CNS Pipeline Products, 2010 42
Table 14: Axxonis Pharma AG-CNS Pipeline Products, 2010 43
Table 15: Avicena Group Inc.-CNS Pipeline Products, 2010 44
Table 16: Solvay Pharmaceuticals-CNS Marketed Products, 2010 45
Table 17: Solvay Pharmaceuticals-CNS Pipeline Products, 2010 46
Table 18: Impax Laboratories-CNS Marketed Products, 2010 47
Table 19: Impax Laboratories-CNS Pipeline Products, 2010 47

List of Figures
1.2 List of Figures
Figure 1: Global Parkinson's Disease Market Revenue($m) Forecast 2001-2009 7
Figure 2: Global Parkinson's Disease Market Revenue($m) Forecast 2009-2016 8
Figure 3: Opportunity and Unmet Need in the Parkinson's Disease Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Parkinson's Disease, 2010 11
Figure 5: Technology Trends Analytic Framework of the Parkinson's Disease Pipeline, 2010 21
Figure 6: Technology Trends Analytic Framework of the Parkinson's Disease Pipeline-Description, 2010 21
Figure 7: Parkinson's Disease Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 28
Figure 8: Parkinson's Disease Pipeline-Pipeline by Clinical Phases of Development, 2010 28
Figure 9: Implications for Future Market Competition in the Parkinson's Disease Market, 2010 38
Figure 10: Parkinson's Disease Therapeutics Market-Clinical Pipeline by Company, 2010 40
Figure 11: GlobalData Methodology 50
Figure 12: GlobalData Market Forecasting Model 53